Search
Showing results for "Childhood interstitial lung disease "
Jonathan Raewyn Carol Carapetis AM Mutch Bower AM MBBS FRACP FAFPHM PhD FAHMS MBChB., DipRACOG., Cert.HPRT, FRACP., PhD MBBS MSc PhD FAFPHM DLSHTM
A summary of the literature regarding the use of adjunctive protein synthesis inhibitors for toxin suppression in the setting of S. aureus infections is presented
This study aims to establish the current knowledge, attitudes, experiences and practices regarding FASD and other neurodevelopmental impairments among youth custodial officers
Find information about ORIGINS Kids Checks, what you need to do before your appointment, and other questionnaire timepoints.
While early exposure to alcohol may influence the development of facial structures, it does not appear to be associated with ASD phenotypic variability
Amy Andrew Helen Jenny Martyn Melissa Videos Finlay-Jones Whitehouse Watch and listen to Andrew Leonard Downs Symons Licari BPsych(Hons), MPsych(
The Adolescent Health and Wellbeing team works in partnership with young people to understand their priority needs and the best ways to address these. This includes informing evidence-based policies and co-designing accessible and responsive health services.
A dramatic rise in food allergies over the past 20 years had Australian medical professionals scratching their heads, with three in every ten babies born each year developing food-related allergy or eczema.
Delays within the motor domain are often overlooked as an early surveillance marker for autism. The present study evaluated motor difficulties and its potential as an early predictive marker for later autism likelihood in a cohort of infants showing early behavioral signs of autism aged 9-14 months. The motor domain was evaluated using the motor subscales of the Mullen Scales of Early Learning at baseline, and at a 6-month follow-up.
Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL.